Management Comment " [...] our end-of-phase-II meeting with the FDA. In this phase II face-to-face meeting, which is scheduled for early second quarter, we will, number one, review and discuss our phase II data; and number two, review the proposed trials design and endpoints for our phase III study. We will then incorporate the FDA comments and recommendations into our trial protocol."
-Joseph Kim CEO